A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

• Status: Recruiting
• Trial end date: 2022-12-01

Summary

This study aims to compare the efficacy of intercalating chemotherapy (gefitinib and pemetrexed/cisplatin) and chemotherapy (navelbine/cisplatin) in completely resected NSCLC with common EGFR mutations.

• Phase: Phase 3

Details

• Lead Sponsor: Yonsei University
• Treatments: Cisplatin; Gefitinib; Pemetrexed; Vinorelbine